MY008211A Tablets for PNH Patients Naive to Complement Inhibitors

This clinical trial is focused on testing a new tablet called MY008211A for patients with a rare blood disorder known as Paroxysmal Nocturnal Hemoglobinuria (PNH). The study specifically targets individuals who have not previously received treatments known as complement inhibitors. The goal is to see if MY008211A is safe and effective compared to an existing treatment called eculizumab. This study is important because finding effective treatments can improve the quality of life for people with PNH and offer new options for those who have never tried these types of medications before. Participants in this study are randomly assigned to receive either the MY008211A tablets or eculizumab. The study is open-label, meaning both the participants and the researchers know which treatment is being administered. The main focus is to evaluate how well MY008211A works in comparison to eculizumab and to monitor any side effects or safety concerns. By comparing the two treatments, the study aims to gather valuable information on the effectiveness and safety of the new tablet, which could lead to better treatment options for PNH patients.